Robert Meadowcroft | CEO
The Muscular Dystrophy U.K.

Robert Meadowcroft, CEO, The Muscular Dystrophy U.K.

Robert Meadowcroft, Chief Executive, Muscular Dystrophy UK Robert Meadowcroft was appointed Chief Executive of Muscular Dystrophy UK in 2010 after joining the charity as Director of Policy and Operations in 2006. His leadership experience at several national charities enabled Robert to lead Muscular Dystrophy UK to develop partnerships in research and establish effective campaigns which have resulted in huge improvements in care and support for people with muscle-wasting conditions. Key areas of progress include working with regulators to ensure patients have access to the first drug to treat an underlying cause of muscular dystrophy, and gaining parliamentary approval for the introduction of mitochondrial transfer IVF in the UK, a step that received world-wide attention. An effective media spokesperson, Robert has engaged people living with a muscle-wasting condition in many aspects of the charity’s work.

Appearances:



Day One World Pharma Pricing & Market Access EU Congress @ 09:40

Keynote panel: Engaging all key stakeholders to improve access and pricing

  • Overview of European and global initiatives and next steps
  • How can we work better for the patient?
  • Working with payers, patients and pharma to generate value

Day One World Pharma Pricing & Market Access EU Congress @ 11:25

Ensuring the patients voice in reimbursement for rare diseases

back to speakers